Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment — 94.1 percentage of participants

Primary: Clinical Performance by Cvar & Ryge Scores — 96.6; 88.3; 100.0; 100.0 percent of teeth — p=0.8

Primary: Change in Pain Level From Baseline to 45 Minutes — 1.2; 3.7 units on a scale

Primary: Modeled Hgb Change From Baseline Over 4 Weeks of Treatment — -0.148; 0.132; 0.463; 1.010 gram per decilitre (g/dL) — p=0.5888

Primary: Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose) — 1.94; 2.86; 2.03; 2.94 units on a scale

Primary: Wake After Sleep Onset (WASO) — 117.33; 88.0; 81.00; 65.56 minutes

Primary: Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24 — 58; 14; 60; 30 Participants — p=<0.001

Primary: Change in Authorization Rates for Solid Organ Donation From Families of Donor-eligible Patients — 78; 80; 89; 81 Percentage of successful requests

Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants

Primary: Change in Lower Extremity Fugl-Meyer Score at End of Treatment — 1; 1.7 units on a scale

Primary: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV — 80.3; 0; 96.2; 15.4 Percentage of participants

Primary: Treatment Response — 21; 44; 25; 50 Percentage of Participants

Primary: Change in Axial Length — 0.153; 0.087; 0.082; 0.059 mm

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A — 0; 2; 0; 0 Participants

Primary: Tampon Test Pain Intensity — 4.29; 3.96 units on a scale — p=0.07